New Study Puts a Dollar Figure on the Cost of Living with Interstitial Cystitis

A large real-world claims study has quantified just how costly interstitial cystitis/bladder pain syndrome (IC/BPS) is to manage in the US healthcare system — with newly diagnosed patients incurring more than double the healthcare costs of people without the condition.

In this article:

• What the study measured
• What the costs looked like
• How costs changed over time
• Why this matters for IC/BPS patients

What the Study Measured

Published in the Journal of Medical Economics in August 2026, the study used claims data from the Merative MarketScan Commercial and Medicare Supplemental Databases, covering records from 2016 through mid-2025. Researchers matched patients newly diagnosed with IC/BPS to a control group without the condition, then compared healthcare resource utilization and costs across a one-year baseline period and three years of follow-up.

What the Costs Looked Like

In the first year after diagnosis, IC/BPS patients averaged $21,848 in total healthcare costs per patient, compared to roughly $9,200 for the matched control group — more than double. The cost gap spanned inpatient, emergency department, outpatient, and pharmacy spending, not just one category of care.

How Costs Changed Over Time

Costs for IC/BPS patients declined somewhat after the first year but remained elevated well above the control group, settling around $17,888 per patient per year by year three. Costs for the control group, by contrast, stayed relatively flat throughout the study period at roughly $9,200 per year.

Why This Matters

This adds a hard financial figure to what IC/BPS patients already know from experience: this is an expensive condition to manage, and the burden doesn't disappear quickly after diagnosis. The elevated costs likely reflect the diagnostic difficulty of IC/BPS — a condition diagnosed by ruling out other causes — along with the ongoing cycle of specialist visits, testing, and trial-and-error treatment many patients go through. For patients and caregivers navigating insurance coverage or treatment decisions, this data offers a concrete benchmark for the scope of long-term costs to plan around.

Conclusion

The findings reinforce a pattern seen in smaller, older studies of IC/BPS costs, but with more current, large-scale claims data. It's a reminder that the toll of chronic bladder pain conditions extends well beyond symptoms — into years of elevated financial strain for patients trying to get answers and relief.

Sources

• Journal of Medical Economics, "Real-world all-cause healthcare resource utilization and costs among patients with interstitial cystitis/bladder pain syndrome in the United States" (published online August 11, 2026): tandfonline.com